Renaissance Technologies LLC Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

Renaissance Technologies LLC purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 138,200 shares of the company's stock, valued at approximately $1,472,000. Renaissance Technologies LLC owned approximately 0.59% of UroGen Pharma as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in URGN. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the fourth quarter valued at about $59,000. Oppenheimer & Co. Inc. acquired a new position in shares of UroGen Pharma in the fourth quarter valued at approximately $126,000. Legal & General Group Plc increased its position in shares of UroGen Pharma by 24.6% during the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock worth $211,000 after acquiring an additional 3,920 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of UroGen Pharma by 44.1% during the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock worth $216,000 after acquiring an additional 6,207 shares during the period. Finally, Privium Fund Management B.V. bought a new stake in UroGen Pharma in the 4th quarter valued at $295,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on URGN. HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of UroGen Pharma in a research note on Monday. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research note on Monday. The Goldman Sachs Group lowered their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Finally, Scotiabank began coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $32.86.

UroGen Pharma Stock Performance

NASDAQ URGN opened at $11.26 on Tuesday. The firm has a market capitalization of $519.02 million, a P/E ratio of -3.57 and a beta of 0.80. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm's fifty day moving average price is $10.44 and its two-hundred day moving average price is $11.08. UroGen Pharma Ltd. has a 1 year low of $8.94 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. As a group, research analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Insider Activity

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now directly owns 145,666 shares of the company's stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company's stock.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.